BMY - Bristol-Myers Squibb Company - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

BMY is currently covered by 18 analysts with an average price target of $57.43. This is a potential upside of $11.45 (24.9%) from yesterday's end of day stock price of $45.98.

Bristol-Myers Squibb Company's activity chart (see below) currently has 200 price targets and 201 ratings on display. The stock rating distribution of BMY is 25% BUY, 62.5% HOLD and 12.5% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 67.23% with an average time for these price targets to be met of 669.77 days.

Highest price target for BMY is $73, Lowest price target is $34, average price target is $58.87.

Most recent stock forecast was given by TERENCE FLYNN from MORGAN STANLEY on 10-Jul-2025. First documented stock forecast 22-May-2013.

Currently out of the existing stock ratings of BMY, 14 are a BUY (25%), 35 are a HOLD (62.5%), 7 are a SELL (12.5%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Sell

$34

$-14.43 (-29.80%)

$39

20 days ago
(10-Jul-2025)

10/13 (76.92%)

$-14.52 (-29.93%)

137

Buy

$68

$19.57 (40.41%)

3 months 7 days ago
(23-Apr-2025)

2/3 (66.67%)

$19.47 (40.12%)

18

Buy

3 months 8 days ago
(22-Apr-2025)

3/4 (75%)

$20.88 (37.88%)

652

Hold

$54

$5.57 (11.50%)

$43

3 months 19 days ago
(11-Apr-2025)

1/4 (25%)

$3.29 (6.49%)

12

Hold

$62

$13.57 (28.02%)

$52

5 months 23 days ago
(07-Feb-2025)

6/8 (75%)

$5.15 (9.06%)

48

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is BMY (Bristol-Myers Squibb Company) average time for price targets to be met?

On average it took 669.77 days on average for the stock forecasts to be realized with a an average price target met ratio 67.23

Which analyst has the current highest performing score on BMY (Bristol-Myers Squibb Company) with a proven track record?

CHRIS SCHOTT

Which analyst has the most public recommendations on BMY (Bristol-Myers Squibb Company)?

Chris Schott works at JPMORGAN and has 6 price targets and 6 ratings on BMY

Which analyst is the currently most bullish on BMY (Bristol-Myers Squibb Company)?

Chris Schott with highest potential upside - $31.57

Which analyst is the currently most reserved on BMY (Bristol-Myers Squibb Company)?

Terence Flynn with lowest potential downside - -$14.43

Bristol-Myers Squibb Company in the News

Prime Medicine soars as Jones sees it as an acquisition target

[Genetic engineering, GMO and Gene manipulation, DNA gene editing, CRISPR-Cas9] CIPhotos/iStock via Getty Images * Prime Therapeutics (NASDAQ:PRME [https://seekingalpha.com/symbol/PRME]) skyrocketed ~35% Monday after JonesTrading issued a bullish report on the company due to increased interest in gene editing in the wake of Eli Lilly’s (NYSE:LLY [https://seekingalpha.com/symbol/LLY]) deal [https://seekingalpha.com/news/4458710-eli-lilly-to-acquire-for-verve-therapeutics-for-up-to-13b] last month to pay up to $1.3B...

Validea Detailed Fundamental Analysis - BMY

Below is Validea’s guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?